Category: Mergers and Acquisitions

  • JT Group Completes Vector Group Acquisition

    JT Group Completes Vector Group Acquisition

    Image: somchaij

    The JT Group completed the acquisition of Vector Group (VGR) on Oct. 7, following a tender offer, initially announced on Aug. 21.

    The tender offer period, initiated on Sept. 4, 2024, expired at one minute after 23:59 Eastern Daylight Time, on Oct. 4, 2024. The conditions of the tender offer having been satisfied, the JT Group has accepted all such tendered shares, and, following a statutory merger on Oct. 7, 2024, VGR became a wholly owned subsidiary of the JT Group and was delisted from the New York Stock Exchange on Oct. 7, 2024.

    In a statement, the JT Group said it expects the acquisition to improve the company’s return-on-investment in combustibles by significantly increasing the group’s presence and distribution network in the U.S, the second largest tobacco market in net sales and one of the most profitable.

  • PMI to Record £220 Million Loss on Vectura Sale

    PMI to Record £220 Million Loss on Vectura Sale

    Image: Aliaksandr Marko

    Philip Morris International expects to record a record loss of about £220 million ($198 million) on the sale of its inhaled-therapeutics Vectura Group unit to Molex Asia Holdings in the third quarter, reports The Wall Street Journal, citing a securities filing.

    On Sept. 17, PMI’s pharmaceutical subsidiary, Vectura Fertin Pharma, announced it would sell its Vectura Group business to Molex. The company acquired Vectura Group in 2021 for $1.24 billion as part PMI’s drive to diversify beyond nicotine.

    The company now says that “unwarranted opposition” to its transformation has affected Vectura Group’s engagement with the scientific community and its commercial relationships.

    The remaining units of Vectura Fertin Pharma will continue to operate under a new corporate identity and develop oral consumer health and wellness offerings, as well as inhaled prescription products for pain management and cardiovascular emergencies.

  • Arcus Compliance Purchases Data Firm VapeClick

    Arcus Compliance Purchases Data Firm VapeClick

    Photo: Khanchai

    Regulatory compliance consultancy Arcus Compliance has acquired vape industry data platform VapeClick.

    VapeClick is a comprehensive online directory of U.K. Medicines and Healthcare products Regulatory Agency submitted and notified vape and e-cigarette product data.

    The platform enables vape industry stakeholders to search and identify appropriately published and notified products. VapeClick supports a wide variety of use cases, offering bespoke reporting and notifications from its vape intelligence application.

    “We are delighted to have agreed the deal to acquire the vape-click.com portal,” said Arcus Compliance CEO Lee Bryan. “The solution has become the go-to portal for U.K.-registered vape products and will become an important piece of the jigsaw for the cutting-edge Arcus software portfolio. We have exciting plans for integration, including development for other industries as well as providing valuable oversight for enforcement bodies throughout Europe.”

    “This is an important milestone in the growth and development of the innovative vape-click.com platform,” said VapeClick’s Chief Technical Officer Raphael Klimaszewski. “We have spent many years building the database that has revolutionized how vape products can be quickly and readily checked and monitored for their compliance status.

    “The acquisition of the portal by Arcus Compliance is a testament to the impact that the platform has made and its inherent value amongst its many users. We look forward to seeing it go from strength to strength under Arcus’ leadership.”

  • BAT Invests Another $90.5 Million in Organigram

    BAT Invests Another $90.5 Million in Organigram

    Credit: Roxxy Photos

    Organigram Holdings Inc. has extended its relationship with British American Tobacco. The move boosts the Canadian cannabis producer’s financial strength and positioning it to expand globally.

    Organigram said in a statement that BAT is investing a further $90.5 million in the business, building on an initial $160 million injection back in 2021.

    Organigram said the investment will allow it to extend its footprint beyond Canada, and also strengthen its financial position for long-term, sustainable growth, according to media reports.

    “This investment bolsters an already strong balance sheet and solidifies our position as a leading cannabis company,” said Beena Goldenberg, chief executive of Organigram.

    The firm said the deal enables it to invest in growing the topline of its core business, while optimizing operations to deliver on cost-saving efficiencies, thus accelerating earnings growth.

    Organigram will use the majority of the investment to create a strategic investment pool, named Jupiter.

    Jupiter will target investments in emerging cannabis opportunities that will enable Organigram to apply its industry-leading capabilities to new markets, it said.

  • Altria’s Acquisition of Njoy Comes to a Close

    Altria’s Acquisition of Njoy Comes to a Close

    Image: Tobacco Reporter archive

    Altria Group has completed its acquisition of Njoy Holdings. The tobacco giant has also updated its guidance for 2023 full-year adjusted diluted earnings per share (EPS) in connection with the transaction.

    “The completion of this transaction is a transformative step in our goal of ‘Moving Beyond Smoking,’” said Billy Gifford, Altria’s CEO. “We are pleased to have received antitrust clearance, and we are now fully focused on responsibly accelerating U.S. adult smoker and adult vaper adoption of Njoy Ace, currently the only pod-based e-vapor product to receive marketing authorization from the FDA.

    “Our updated 2023 full-year EPS guidance range includes planned investments behind the U.S. commercialization of Njoy Ace and reflects our goal to deliver strong shareholder returns while making progress toward our vision.”

    “We are excited to combine our resources with Njoy’s talented team to benefit adult tobacco consumers across the country,” said Shannon Leistra, the new president and CEO of Njoy.

    As a result of the transaction, Altria expects to deliver 2023 full-year adjusted diluted EPS in a range of $4.89 to $5.03, representing a growth rate of 1 percent to 4 percent from an adjusted diluted EPS base of $4.84 in 2022.

    “Our 2023 full-year adjusted diluted EPS guidance range includes planned investments in support of the company’s vision, such as (i) continued smoke-free product research, development and regulatory preparation expenses, (ii) enhancement of the company’s digital consumer engagement system and (iii) marketplace activities in support of the company’s smoke-free products, including planned investments behind the U.S. commercialization of Ace,” Altria wrote in a press note.

    Altria’s updated guidance range also includes estimated amortization charges of approximately $50 million for the remainder of 2023 related to intangible assets acquired in the transaction.

  • Altria Set to Complete Purchase of NJOY Holdings

    Altria Set to Complete Purchase of NJOY Holdings

    Credit: JHVE Photo

    Altria Group today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired in connection with the company’s previously announced pending acquisition of NJOY Holdings.

    This confirms that no further regulatory review by the federal antitrust authorities is required in connection with the transaction. Subject to the satisfaction of other customary closing conditions.

    Altria states that it expects to complete the acquisition in the second quarter of 2023.

    In 2022, the U.S. vapor category comprised nearly 14 million U.S. adult tobacco consumers, including 9.5 million exclusive adult vapers, according to Altria. The segment generated approximately $7 billion in U.S. retail sales and represented approximately 15 percent of total estimated equivalized U.S. tobacco volumes and more than 50 percent of total estimated equivalized smoke-free tobacco volumes.

    To date, the U.S. Food and Drug Administration has approved the marketing of 23 vapor products and devices. In 2022, NJOY received marketing granted orders for the NJOY Ace device, along with several tobacco-flavored pods. The regulatory agency is still reviewing NJOY’s premarket tobacco product applications for several NJOY menthol-flavored e-vapor products.

    Altria said it had multiple sources of funding for the deal, including cash from a $2.7 billion agreement with Philip Morris International last year for the IQOS Tobacco Heating System.

    The NJOY deal followed an announcement by Altria that it would exchange its entire minority investment in embattled Juul Labs for a nonexclusive global license for certain of Juul’s heated tobacco intellectual property.

    In total, Njoy Holdings has received six of the 23 marketing orders granted by the FDA as of this writing for the entire vaping product category, including pods, disposables and open systems.

    A major factor in Altria purchasing Njoy is the Ace device didn’t come with the stigma tied to youth vaping, according to Altria CEO Billy Gifford.

    “We believe Njoy has taken a responsible approach to marketing its products. According to the 2022 National Youth Tobacco Survey, Njoy-branded products are not included among the top usual brands among middle school and high school e-cigarette users. Additionally, Njoy is developing access restriction technology for its devices to further address underage use,” explains Gifford. “Our consumer research indicates that once consumers try Njoy Ace, it is a competitive product for both smokers and vapers. After trying the authorized nonmenthol Ace variant, 19 percent of surveyed smokers and 27 percent of surveyed vapers indicated that they would definitely buy the product.”

  • Reports of Possible $5 Billion Offer Coming for NJOY

    Reports of Possible $5 Billion Offer Coming for NJOY

    E-cigarette maker NJOY Holdings Inc has hired bankers for a possible sale of the company, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.

    The report added the privately held NJOY is likely to be valued at up to $5 billion, according to the sources who cautioned the process was still at an early stage and there was no guarantee a deal would materialize.

    If NJOY does not receive a high enough valuation, the company could raise money and stay private, potentially paving the way for a future initial public offering, the Wall Street Journal said.

    The e-cigarette maker is simultaneously exploring a new fundraising round and aims to raise between $300 million and $500 million, the report added.

    NJOY has two devices that have received marketing approval from the U.S. Food and Drug Administration, including its Ace device and Daily disposables.

    Late June, Bernstein analyst Callum Elliott wrote in a note that Altria could try to buy privately owned NJOY, which “has already succeeded with its PMTA process applications.”

    Rival Juul Labs Inc said on Friday it was in the early stages of exploring several options, including financing alternatives, as the company deals with lawsuits and a probable ban on sales of its e-cigarettes by U.S. health regulators.

    NJOY and Mudrick Capital Management, a majority owner of the company, did not immediately respond to a Reuters request for comment.

  • ReStalk Partners With Fiber Company to Process Hemp

    ReStalk Partners With Fiber Company to Process Hemp

    ReStalk, Inc has entered into a licensing agreement with Sustainable Fiber Technologies (SFT) enabling the company to utilize the SFT’s suite of IP to process hemp into cellulose pulp and biopolymers. These polymers are used to make vapor product packaging, among many other items.

    hemp fiber
    Credit: ReStalk

    The partnership allows SFT to assist ReStalk in the developing hemp-based pulp and board products. “ReStalk is an excellent company with the foresight into both the paper and packaging arena. Their team and expertise of hemp cultivars makes ReStalk a perfect licensee for the Phoenix Process,” said Mark Lewis CEO of SFT. “Domestically, the demand for hemp pulp has never been higher, it provides a quality non-wood fiber that competes with softwood fiber.”

    ReStalk’s first project with the SFT license will be building a a pulp mill capable of producing100 tons-per-day of pulp. “We’re eager to provide the infrastructure needed to stabilize this re-emerging crop,” said Lucas Hildebrand, ReStalk’s chief strategy officer. “This project will strengthen the supply chain and manufacturing of hemp’s downstream products here in the US. We’re excited to get to work and lay the foundation for a more regenerative model of production.”

    As the pandemic caused by COVID-19 continues to disrupt global supply chains, the need for scalable sustainable solutions has never been more necessary, according to a press release. The mill positions ReStalk as the largest supplier of American manufactured hemp pulp.

    “Consumer demand for new sources of sustainable packaging is accelerating worldwide. Along with forest-based fibers, we see tremendous interest in hemp and similar alternative agricultural fibers,” said Warren Pullen, executive vice president for Central National Gottesman, a pulp, paper, packaging, tissue and non-wovens distribution. “We believe ReStalk has the potential to successfully address unmet demand for hemp fiber and take green packaging to the next level.”